|

Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments

RECRUITINGSponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna
Actively Recruiting
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
Started2023-03-15
Est. completion2025-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06764459

Summary

This study aims to analyze patients with mutated FLT3 AML treated with specific therapy by means of molecular characterization methods, to identify the presence of clones and subclones at onset and to be able to follow their evolution during therapeutic treatment.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* FLT3 mutated

Exclusion Criteria:

* Respoder to therapy

Conditions2

CancerMyeloid Leukemia, Acute

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.